Containment Licensing RNA 
pharmaphorum
MAY 26, 2022
His work on a technique known as Hijack RNA, which tricks viruses into killing the cells they infect, underpins Enochian’s antiviral pipeline. The DoJ notes that the indictment charging Gümrükcü and Eratay “contains accusations only, and the defendants are presumed innocent until and unless proven guilty.”
pharmaphorum
MAY 24, 2022
While health authorities are on alert, the WHO said it thinks the outbreak can be contained and that the overall risk to the population remains low. Monkeypox is considered less likely to mutate quickly because it is a DNA virus rather than an RNA virus like influenza or COVID-19.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 13, 2023
Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. million, compared to $1.1 million for the same period in 2022.
Pfizer
DECEMBER 13, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. Disclosure Notice.
The Pharma Data
OCTOBER 14, 2020
is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.
The Pharma Data
JANUARY 21, 2021
In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 50 copies per milliliter [c/mL] at Week 48), with a comparable number of patients receiving either CABENUVA or their daily current antiretroviral regimen (CAR) having an HIV-1 RNA level ?50
The Pharma Data
SEPTEMBER 9, 2020
Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. The information contained in this release is as of September 9, 2020.
Expert insights. Personalized for you.
105 
Let's personalize your content